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Blood pressure and chronic 
kidney disease
From 1999 to 2006 South Africa (SA) has seen 
a 67% rise in deaths owing to chronic kidney 
disease (CKD), and the prevention of this condition 
remains an important priority. Although accurate statistics are 
not available in SA, hypertension and type 2 diabetes mellitus (in 
line with worldwide trends) are the dominant diseases associated 
with end-stage kidney disease (ESKD), particularly in black ethnic 
groups. Levels of systolic and diastolic blood pressure (BP) are 
directly linked to the prevalence of CKD and the components of the 
metabolic syndrome.
Prevention of CKD at the population level requires interventions 
that improve lifestyles that lead to a reduction in BP, obesity, type 2 
diabetes mellitus (DM) and smoking. At the primary practitioner 
level, it is mandatory to measure BP in all adult patients and, if the 
patient has hypertension, to routinely screen for evidence of CKD 
(urine dipsticks, and serum creatinine (with calculate glomerular 
filtration rate (GFR)) and associated comorbidities, such as type 2 
DM. 
Treatment of hypertension without overt CKD
• Patients with established hypertension should be treated 
in accordance with the South African Hypertension Society 
guidelines.
• The goal BP is <140/90 mmHg.[1]
• It is particularly important to recognise patients at greatest 
risk for the development of malignant hypertension and 
progression to ESKD. These patients usually have severe 
hypertension (BP >180/100 mmHg) and are often young, lean 
black males without other major risk factors. It is important to 
initiate combination therapy with at least two antihypertensive 
agents, and patients should be followed up within 7 days to 
assess BP response.
Treatment of hypertension in patients with established CKD
• Hypertension is a cause of CKD and aggravates existing CKD, 
resulting in a vicious cycle. Antihypertensive therapy has been 
proven to disrupt this cycle.
• Hypertension is also a potent risk factor for cardiovascular 
disease (CVD). Control of hypertension prevents cardiovascular 
morbidity and mortality, especially in CKD.
• It is important to understand that the pathogenesis of hypertension 
in CKD is related to overactivity of the renin-angiotensin-
aldosterone and sympathetic nervous systems, and volume 
overload. Angiotension II also plays an important role in the 
progression of CKD. These basic facts underlie the rationale for 
antihypertensive therapy.
• The most important objective of antihypertensive treatment is to 
achieve a BP of <130/80 mmHg; the secondary objective being to 
reduce proteinuria to at least 0.5 g/24 hours or <0.05 g/mmol on 
spot urine.
• Lifestyle changes are an essential adjunct to antihypertensive 
drugs. Smoking cessation, exercise and weight loss are 
encouraged and sodium content of the diet reduced to <100 mmol/day. 
The latter can be checked by 24-hour urinary sodium analysis. Non-
steroidal anti-inflammatory drugs (NSAIDs) and other drugs that raise 
BP or worsen renal function must be avoided.
• In the absence of contraindications (bilateral renal artery stenosis, 
planned pregnancy or history of angioedema (angiotensin-
converting enzyme (ACE) inhibitor only)), ACE inhibitors 
or angiotensin II receptor blockers (ARBs) are the preferred 
first-line drugs of choice, especially if proteinuria is present. 
The agents should be titrated to their maximum recommended 
dosages.
• Treatment with ACE inhibitors and ARBs must be carefully 
monitored, especially in patients with stages 3 and 4 CKD who are 
prone to develop hyperkalaemia and deterioration in renal function, 
particularly if there is prerenal failure owing to overuse of diuretics 
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or inter-current illnesses. However, 
from a physiological perspective, renin-
angiotensin system (RAS) inhibitors cause 
a rise in creatinine owing to a reduction in 
intraglomerular pressure – a 20% or less 
rise in creatinine is acceptable. The RAS 
inhibitor may be continued provided there 
is no further deterioration in renal function 
and the serum K+ remains <5.6 mmol/L. 
However, any greater rise should prompt 
the physician to withdraw the RAS inhibitor 
after excluding dietary contributions. 
• In the majority of patients combination 
therapy is required, often with ≥3 anti-
hypertensive drugs to reach the target BP. 
The next antihypertensive added to the 
RAS inhibitor is either a calcium channel 
blocker or a diuretic or both. Both enhance 
the activity of RAS inhibitors, and calcium 
channel blockers avoid the metabolic side-
effects of diuretics. However, diuretics are 
preferred when volume overload is present. 
• Thiazide or thiazide-like diuretics should 
be used in patients with normal renal 
function, and loop diuretics if renal function 
is impaired. Hydrochlorothiazide can be 
titrated to a dose of 25 mg/day. Furosemide 
should be given in divided doses because of 
its short duration of action.
• If BP control is not achieved, review drug 
adherence; sodium restriction is warranted 
and BP control outside the office with 
either home or 24-hour BP monitoring 
should be assessed to exclude the white 
coat effect. 
• If after this the BP remains at >130/80 mmHg, 
there are two options: add low-dose 
spironlactone 25 - 50 mg/day, provided 
renal function is normal and K+ is carefully 
monitored, or introduce agents that block 
the sympathetic nervous system. A β-blocker 
followed by a long-acting α-blocker or a 
centrally acting sympatholytic-like moxo-
nidine is a rational strategy.
• In recalcitrant patients consider minoxidil, 
but avoid long-term use in females and be 
aware of possible pericardial effusion in 
stages 4 and 5 CKD.
Summary
Control of hypertension is the most 
important factor in the primary prevention 
and progression of CKD. In patients with 
CKD, the goal BP is <130/80 mmHg and 
first-line therapy is the administration 
of an RAS inhibitor. However, multiple 
agents are often required to achieve the 
BP target.
Diabetic patients[2]
• DM is the most common cause of CKD 
worldwide.
• Both type 1 and 2 DM are on the increase.
• The incidence of CVDs is increased in 
diabetic patients.
Diagnosis of diabetic nephropathy
• It normally develops after DM duration 
of >10 years.
The clinical stages of diabetic nephropathy 
are given in Table 1.
Preservation of renal function
• Strict glycaemic control. HbA1c <6.5%.
• BP control. Aim for <130/80  mmHg. 
Avoid systolic BP <110 mmHg.
• Use ACE inhibitors or ARBs as first-line 
therapy.
• Add other classes of BP medications to 
achieve the target BP.
• Reduce proteinuria. Administer ACE 
inhibitors or ARBs for an antiproteinuric 
effect.
• Restrict salt intake (4 - 6 g/24 hours). 
• Prevention of acute kidney injury. Avoid 
nephrotoxins (NSAIDs, aminoglycosides, 
X-ray contrast media).
• Attention to CVD risk. Most patients with 
DM and CKD do not reach stage 5 CKD, 
as they die early owing to CVD.
• Lifestyle and nutrition.[4] Aerobic exercise 
daily for approximately 30 minutes is 
recommended. Smoking should be 
discontinued. Weight should be reduced. 
Patients should be on a protein-restricted 
diet (0.6 - 0.8  g/kg/day predialysis; 
1.2 g/kg/day on dialysis).
Table 1. Clinical stages of diabetic nephropathy[3]
Stage GFR UAE
Blood 
pressure Years
1. Hyperfiltration Super normal <30 mg/day Normal 0 - 5
2. Microalbuminuria High normal - normal 30 - 300 mg/day Rising 5 - 15
3. Overt proteinuria Normal - decreasing >300 mg/day Elevated 10 - 20
4. Progressive nephropathy Decreasing Increasing Elevated 15 - 25
5. ESKD <15 mL/min Massive Elevated 20 - 30
ESKD = end-stage renal disease; GFR = glomerular filtration rate; UAE = urinary albumin excretion.
Table 2. Modifications of antidiabetic drugs in patients with type 2 diabetes mellitus 
(adapted from the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines)
Class Drug 
Dosing recommendation stages 3 and 4 CKD or 
kidney transplant Dosing recommendation dialysis
First-generation 
sulfonylureas
Acetohexamide, tolazamide, 
tolbutamide
Avoid Avoid
Chlorpropamide Avoid when GFR <50 mL/min/1.73 m² Avoid
Second-generation 
sulfonylureas
Glipizide, gliclazide Preferred sulfonylurea
No dose adjustment
Preferred sulfonylurea 
No dose adjustment 
Glyburide Avoid Avoid
Glimepiride Initiate at low dose, 1 mg/day Avoid
α-glucosidase inhibitors Acarbose Not recommended if serum creatinine >180 µmol/L Avoid
Biguanides Metformin See text Avoid
Meglitinides Repaglinide No dose adjustment Avoid
Nateglinide Initiate at low dose (60 mg before each meal) Avoid
Thiazolidinediones Pioglitazone, rosiglitazone No dose adjustment No dose adjustment
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Pharmacological treatment of DM
Patients with stages 3 - 5 CKD are at risk of hypoglycaemia because of:
• decreased renal clearance of insulin and sulfonylureas
• impaired renal gluconeogenesis.
Type 1 DM
Insulin needs may change with decreasing renal function, as CKD 
is associated with insulin resistance and there is decreased renal 
clearance of insulin with advancing CKD.
Type 2 DM
A number of different oral hypoglycaemic drugs are available (Table 2).
The benefits of intensive therapy are independent of the type of 
treatment administered.
Metformin
Metformin should be used with caution in patients with stages 4 and 
5 CKD. Its use in CKD carries a small risk of severe lactic acidosis; 
the risk increases with decreasing glomerular filtration rate (GFR) 
and the dose should be adjusted.
The use of metformin should be reviewed when the patient reaches 
stage 3 CKD and its use is contraindicated in stages 4 and 5 CKD.
Sulfonylureas
First-generation sulfonylureas should be avoided. Second-generation 
sulfonylureas may be used in patients who have learnt to avoid 
hypoglycaemic episodes, as long as their diabetes is controlled and 
nutritional status is satisfactory.
Thiazolidinediones
These may be used in patients without heart failure. Caution is 
advised in patients with ischaemic heart disease.
Insulin
When insulin therapy is used, care should be taken to avoid 
hypoglycaemic episodes, as the renal clearance of insulin declines 
with advancing renal impairment.
Newer antidiabetic drugs
• DPP-4 antagonists (vildagliptin, saxagliptin) can be used with 
dose adjustments. Avoid combination drugs that also contain 
metformin.
• GLP-1 receptor agonists (exenatide, liraglutide). These should 
not be used in moderate renal function impairment (creatinine 
clearance <30 mL/min).
HIV and CKD
Global prevalence of HIV infection
There are an estimated 35 million people infected with HIV, 68% of 
whom are in sub-Saharan Africa (SSA). Southern Africa is the worst 
affected, with the national adult HIV prevalence exceeding 15% in 
eight southern African countries.[5] 
Table 3. Spectrum of renal disease in HIV
• Electrolyte and acid-base disturbances
• Acute kidney injury 
• CKD
• Intrinsic renal disease unrelated to HIV itself (e.g. DM and hypertension)
• HIV-associated glomerulonephropathies: may present as acute-on-chronic or chronic renal failure; this group is primarily implicated in the 
burden of CKD
• Acute-on-chronic kidney disease
• Side-effects related to treatment of HIV (ART and drugs used to treat complications of HIV)
• Long-term metabolic side-effects of ART
Table 4. Spectrum of glomerular disease in HIV
Glomerular pattern Subtypes
HIV-FGS or ‘classic’ HIVAN (HIV-associated nephropathy) Some have described a mixed variant of HIV-FGS in 
combination with a proliferative glomerulonephritis
HIV-ICD (this group of patients may have co-infection with hepatitis B or C) Mesangial proliferative 
Membranoproliferative (type I and III)
Lupus-like
Exudative-proliferative
Crescentic
IgA
Membranous
Various glomerulonephropathies (this is a heterogeneous group with different aetiologies) Minimal change
Immunotactoid
Amyloidosis
HIV-TTP/HUS TTP/HUS
Comorbid disease Diabetic nephropathy
Hypertensive nephrosclerosis
Auto-immune disease (e.g. lupus nephritis)
FGS = focal glomerulosclerosis; HIV-ICD = HIV immune complex disease; TTP = thrombotic thrombocytopenic purpura; HUS = haemolytic uraemic syndrome.
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Spectrum of kidney disease with HIV infection 
There is a wide clinical spectrum of renal disease (Tables 3 and 4) in 
the course of HIV infection.
Acute kidney injury in HIV 
The causes of acute kidney injury (AKI) in hospitalised HIV-
infected patients may be community or hospital acquired, 
the latter being 5 - 10 times more common than the former, 
with a worse outcome in hospital-acquired AKI.[6] The known 
causes of AKI are similar in HIV and non-HIV groups, the 
most common being acute tubular necrosis (ATN), secondary 
to sepsis, hypotension, dehydration and nephrotoxicity. AKI is 
potentially reversible with appropriate medical treatment and, if 
indicated, dialysis support.[6,7] In studies of hospitalised patients 
with HIV infection, AKI occurred in up to 20% of cases, and 
age and ethnicity contributed to mortality. In another study, 
the short-term prognosis in this group of patients showed 
mortality of 18% at 2 months, with 80% of patients diagnosed 
with AIDS at the time of hospital admission. Since the advent 
of ART (antiretroviral treatment), a prospective study on AKI in 
ambulatory HIV-infected outpatients with access to ART concluded 
that more severe immunosuppression (CD4 <200 cells/mm3 and/
or HIV RNA level >10 000 copies/mL) is still the predominant risk 
factor for AKI.[8] 
Table 5. Dose adjustments for ART in CKD and ESKD[19]
Agent CKD (adjusted according to creatinine clearance, or by eGFR) Dialysis
Nucleoside/ nucleotide analogues
Abacavir No adjustment No adjustment. HD: dosing 
independent of dialysis sessions
Azidothymidine/zidovudine (AZT)* Cr cl ≥15 mL/min: no adjustment 
Cr cl <15 mL/min: 100 mg po q 6 - 8 h 
100 mg po q 6 - 8 h*
or 300 mg po qd 
Didanosine (ddi) Weight >60 kg Weight <60 kg Dose for Cr cl <10 mL/min†
Cr cl 30 - 59 mL/min: 200 mg po qd
Cr cl 10 - 29 mL/min: 125 mg po qd
Cr cl <10 mL/min: 125 mg po qd
125 mg po qd
100 mg po qd
75 mg po qd
Emtricitabine‡ Cr cl >50 mL/min: no adjustment
Cr cl 30 - 49 mL/min: 200 mg po q 48 h
Cr cl 15 - 29 mL/min: 200 mg po q 72 h
Cr cl <15 mL/min: 200 mg po q 96 h
200 mg po q 96 h† 
PD: no data
Lamivudine (3TC)* Cr cl >50 mL/min: no adjustment
Cr cl 30 - 49 mL/min: 150 mg po qd
Cr cl 15 - 29 mL/min: 150 mg first dose, then 100 mg po qd
Cr cl 5 - 14 mL/min: 150 mg first dose, then 50 mg po qd
Cr cl <5 mL/min: 150 mg first dose, then 25 mg po qd
150 mg first dose, 
then 25 mg po qd†
Stavudine (d4T) Cr cl >50 mL/min: no adjustment
Cr cl 26 - 50 mL/min: 15 - 20 mg po bid
Cr cl ≤25 mL/min: 15 - 20 mg po qd
20 mg po qd†
PD: has been used safely
Tenofovir‡ Cr cl >50 mL/min: no adjustment
Cr cl 30 - 49 mL/min: 300 mg q 48 h
Cr cl 10 - 29 mL/min: 300 mg q 72 h
300 mg po every 7 days†
Zalcitabine Cr cl ≥40 mL/min: no adjustment
Cr cl 10 - 40 mL/min: 0.75 mg q 12 h
Cr cl <10 mL/min: 0.75 mg q 24 h 
HD: dose for Cr cl <10 mL/min†
PD: no data
Non-nucleoside reverse 
transcriptase inhibitors
No adjustment
Protease inhibitors No adjustment No adjustment
Entry/fusion inhibitor
Enfuvirtide Cr cl ≥35 mL/min: no adjustment
Cr cl <35 mL/min: unknown, use with caution
Unknown, use with caution
CCR5 receptor antagonist
Maraviroc No dosage recommendations
Patients with Cr cl <50 mL/min should only receive maraviroc and 
CYP3A inhibitor if potential benefit outweighs the risk
No data
Integrase inhibitor
Raltegravir No adjustment No adjustment
Cr cl = creatinine clearance; HD = haemodialysis; PD = peritoneal dialysis.
*Combination AZT/lamivudine tablets (300 mg/150 mg) should be administered separately when eGFR <50 mL/min. 
†Defer daily dose/s after haemodialysis (extraction of drug occurs on dialysis).
‡Combination emtricitabine/tenofovir tablets (200 mg/300 mg). If Cr cl 30 - 49 mL/min: 1 tablet po q 48 h; if Cr cl <30 mL/min, the combination tablet should not be prescribed. 
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HIV-associated CKD (HIV-CKD)
Screening studies from Africa differ widely 
in their reported prevalence of kidney disease 
in HIV. In most studies the prevalence of 
kidney disease has been assessed on the 
presence of albuminuria and/or estimated 
GFR (eGFR) (based on creatinine clearance). 
Studies from Africa have shown a variable 
prevalence of renal disease in HIV, ranging 
from 6% to 45% (6% in SA, 38% in Nigeria, 
26% in Cote d’Ivoire, 28% in Tanzania, 25% 
in Kenya, 20 - 48.5% in Uganda, and 33.5% 
in Zambia), depending on the populations 
studied and the criteria for diagnosis of 
kidney disease. Part of this wide variation 
may be ascribed to differences in study 
design, populations studied and definitions 
used for CKD. Recent literature recommends 
the CKD-EPI formula as the most reliable in 
calculating eGFR in this patient population.[9] 
Very few studies detail the histological pattern 
of kidney disease on kidney biopsy and, 
fewer still, the response to treatment. 
HIV-associated nephropathy (HIVAN)
Most African patients with HIVAN present 
late, with advanced kidney failure. This 
late detection of HIVAN could be because 
of a lack of screening for proteinuria and/
or renal dysfunction and the relative 
absence of overt symptoms and signs, such 
as peripheral oedema and hypertension. 
Patient outcomes with HIVAN have been 
correlated with the clinical stage of their 
disease, suggesting that survival improves 
with earlier detection.[10] There is an 
increased relative risk of 2.5 - 3.0 for overall 
mortality with proteinuria after correcting 
for other risk factors. In one study, 77% of 
renal abnormalities developed with CD4 
counts >200 cells/mm3.[11] This was also 
seen in a study from SA where the mean 
CD4 count of those with biopsy-proven 
HIVAN was 232 cells/mm3.[12] HIVAN 
has been revised by the World Health 
Organization (WHO) as stage 4 disease, 
thus emphasising the need for initiation 
of ART in this condition, irrespective of 
the CD4 count. The initial description of 
HIVAN in individuals of African descent 
has been attributed to the presence of 
APOL1 genetic variants.[13] 
Screening for CKD in HIV 
Statistics in the USA estimate the incidence 
of HIVAN as 3.5 - 12%.[14] If this were 
to be extrapolated to SSA, where an 
estimated 22 million are infected with HIV, 
between 770 000 and 2.64 million people 
would be predicted to have HIVAN. With 
the advent of wider access to ART, the 
epidemiological pattern of HIVAN that 
evolved in the USA over the last 14 years 
Table 6. Common drug-drug interactions with ART[19]
Class of drug Concomitant medication Effect
PIs Anticoagulant: warfarin Variable, check INR
Anticonvulsants: carbamazepine, phenobarbital, phenytoin Variable, recommend therapeutic drug monitoring
Antifungals: ketoconazole, itraconazole, voriconazole Levels of antifungals increased
Calcium channel blockers: diltiazem, nifedipine, verapamil, 
amlodipine, nicardipine, isradipine, felodipine, bepridil
Levels of CCBs increased
Life-threatening arrhythmias with bepridil
HMG-CoA reductase inhibitors (statins): lovastatin, 
simvastatin, atorvastatin
Levels of statins increased – risk of myopathy/
rhabdomyolysis
Preferred: pravastatin, rosuvastatin, fluvastatin
Immunosuppressive drugs: cyclosporine, tacrolimus, sirolimus Levels of immunosuppressive drugs increased, recommend 
therapeutic drug monitoring
Opioids: methadone Levels of methadone may decrease; therefore, may have to 
increase dose
PDE5 inhibitors: sildenafil, vardenafil, tadalafil Levels of PDE5 inhibitors increased, decrease dosage and 
increase dosing interval
Tricyclic antidepressants: amitriptyline, imipramine, 
desipramine, trazodone
Levels of tricyclic antidepressants increased
NNRTIs Calcium channel blockers: warfarin, anti-arrhythmics, PDE5 
inhibitors, cyclosporine
Plasma concentrations, clinical effects, and toxicities of 
concomitant medications should be closely monitored
NNRTIs have less of an effect than PIs
Delaviridine Statins* Levels of statins significantly increased
Anticonvulsants Carbamazepine, phenobarbital, phenytoin contraindicated 
due to very low levels of delaviridine
Glucocorticoids Levels of glucorticoids increased
Immunosuppressives Levels of sirolimus and tacrolimus increased
Efavirenz Statins Levels of atorvastatin and simvastatin decreased
Glucocorticoids Levels of glucocorticoids decreased
Nevirapine Fluconazole Fluconazole may double nevirapine levels 
Glucocorticoids Levels of glucocorticoids decreased
NRTIs 
and fusion 
inhibitors
Little or no effect on hepatic cytochrome P450 
metabolism
Few drug-drug interactions
PI = protease inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; CCB = calcium channel blocker. 
*Levels not affected by nevirapine and efavirenz. 
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may predict what will happen in SSA. 
This presents a potentially unprecedented 
burden of CKD. The Infectious Diseases 
Society of America published guidelines for 
the management of CKD in HIV in 2005, 
with a revision in 2014, which included 
recommendations for screening,[9] e.g. all 
individuals should be assessed for kidney 
disease at the time of diagnosis of HIV 
infection and annually thereafter, with a 
screening urinalysis for proteinuria and 
estimation of renal function. It is important 
when interpreting the significance of 
proteinuria that it is persistent, as false 
positives are common in patients who 
may have comorbid conditions such as 
infection. Failing to confirm persistence 
of proteinuria can significantly impact on 
the number of referrals in high-prevalence 
populations. Any patient with persistent 
proteinuria, persistent haematuria or a GFR 
<60  mL/min/1.73 m2 should therefore be 
referred to an institution where a specialist can 
evaluate the patient. An important caveat 
is that if no referral system is available, 
clinicians should initiate ART as early as 
possible to prevent progression to end-stage 
kidney diseases (ESKD). Considering the 
resource limitations in SSA, with particular 
reference to renal replacement therapy 
(RRT), it is imperative that screening, 
early detection and treatment of HIV-CKD 
be a public health priority. A screening 
algorithm (Fig. 1) is proposed for this 
purpose, accommodating resource-limited 
settings. 
ESKD due to HIV-CKD
Life expectancy in HIV-infected patients 
has increased by 10 - 20 years in developed 
countries with the use of ART; many of 
these patients are now dying from the 
complications of ESKD and other chronic 
diseases, rather than HIV infection. 
Currently, HIV-infected patients requiring 
either haemodialysis or peritoneal dialysis, 
who are stable on ART, are achieving 
survival rates comparable with those of 
dialysis patients without HIV infection. The 
choice of dialysis modality does not impact 
on survival.[16] 
Transplantation has been performed with 
success in HIV-infected patients. Preliminary 
short-term data in liver, kidney, and heart 
transplant recipients suggest that patient 
survival rates are similar to those in high-
risk HIV-uninfected transplant recipients and 
there has been no increase in the prevalence 
of opportunistic infections. In spite of high 
rates of acute graft rejection, survival appears 
to be similar to high-risk HIV uninfected 
recipients.[17] In areas with high endemic rates 
of HIV infection, in view of the shortage 
of donor organs, it has been proposed that 
HIV-infected cadaveric donor organs may 
be transplanted into HIV-infected recipients 
with ESKD. Four such transplants have 
been reported in Cape Town, with good 
graft and recipient survival, but the data are 
preliminary. A further >20 such transplants 
have been performed, with good results.[18]
Drugs and HIV-CKD
In addition to ART, patients are treated for 
opportunistic infections, malignancies, and 
comorbid chronic illnesses (DM/hypertension) 
and may be given immunosuppression 
for kidney transplantation. HIV-CKD is 
compounded by the nephrotoxic potential of 
long-term ART. 
Dosing of ART in CKD
Many ARTs are partially or completely 
eliminated by the kidney and require dose 
adjustment in CKD; hence the necessity 
to measure renal function (Table 5). 
Certain drug classes, such as the protease 
inhibitors (PIs) and the non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), 
are metabolised by the liver and do not 
require dose adjustment. Entry/fusion 
inhibitors, integrase inhibitors, and CCR5 
receptor antagonists also do not require 
dose adjustment.[19] Most of the NRTIs 
are excreted unchanged in the urine and 
require dose adjustment, with the exception 
of zidovudine and abacavir, which have 
substantial extrarenal biotransformation 
requiring less or no dose adjustment. 
Factors that influence dialysability of ART 
relate to the properties of the dialysis 
membrane and molecular weight, degree 
of protein binding, molecular charge and 
water solubility of the drug. If removal 
of a drug occurs during haemodialysis, it 
should be taken after dialysis. If the drug is 
removed in peritoneal dialysis effluent, the 
dose may have to supplemented. Dosing 
recommendations in both haemo- and 
peritoneal dialysis are limited by the lack 
of reliable data. Fixed drug combinations 
should not be used in patients with an 
eGFR <30 - 50 mL/min.[19] 
Drug interactions 
The NNRTIs and PIs are metabolised and 
eliminated by the hepatic and intestinal 
cytochrome P450 enzyme system, in 
particular CYP3A4 and P-glycoprotein. Most 
interactions are a consequence of enzyme 
induction or inhibition and there are many 
drug-drug interactions (Table 6). Certain over-
the-counter preparations can affect drug levels, 
such as St John’s Wort (Hypericum perforatum), 
which induces enzyme induction, causing 
lower PI and NNRTI levels. Concomitant use 
is not recommended.[19] 
Table 7. Other causes of CKD
Disorder
Age groups Ethnic groups
<45 years >45 years Black Other
Congenital/ inherited
• ADPKD + ++
• RTA +
Glomerular disease
• Primary +++ ++ +
• Secondary + + +
• PSGN + +
• SLE +++ + ++ +
• Malignancies (e.g. myeloma) + + +
Viral (not HIV)
• Hepatitis B ++ ++ +
• Hepatitis C +/- +/- +/-
Renovascular* + ++ +/- ++
Obstructive uropathy + + + ++†
Chronic pyelonephritis ++ + +/- ++
Renal calculi ++ + +/- +++
Toxicity (medication) +++ + + +++‡
ADPKD = autosomal-dominant polycystic kidney disease; PSGN = post-streptococcal glomerular nephritis; 
RTA = renal tubular acidosis; SLE = systemic lupus erythematosus; +/-, +, ++, +++ = frequency of diagnosis.
*Renovascular disease in young blacks, e.g. Takayasu syndrome (rare), or in older other ethnic groups, i.e. atheromatous.
†Prostatic diseases.
‡Toxicity of therapeutic medicines.
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Summary
The extent of the HIV epidemic and its associated burden of CKD 
in SSA, coupled with the cost of RRT in a resource-limited setting, 
make it a challenging problem. The current stark reality in SA 
and many developing countries is that most people with ESKD 
and HIV die; some have limited access to dialysis. Most clinicians 
deal with advanced stages of CKD in HIV and prevention or early 
detection of renal disease in this population is neglected. Primary 
healthcare practitioners need a working system for screening, 
early detection and referral. Referral centres require resources for 
Urine dipstick test for leucocytes  
If leucocytes and/or nitrites are present: urine microscopy and culture 
Urinary tract infection (UTI) symptoms: treat empirically, adjust treatment according to 
culture results if indicated 
Sterile pyuria: exclude sexually transmitted infection (STI) (including syphilis) and/or 
tuberculosis 
Repeat urine dipstick at follow up visit 
 
 
Assessment for kidney disease in all HIV
-infected individuals at presentation 
Risk factors:  black race, family history of CKD, use of nephrotoxic agents (including 
traditional medicines), diabetes mellitus, hepatitis C, HIV viral load >4 000 copies/mL,
 000 copies/mL, 
CD4 count <200 cells/mL
3 
Investigations: urine dipstick and serum creatinine, calculate eGFR (CKD-EPI formula) 
!
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Urine dipstick test for proteinuria  
If negative, test for microalbuminuria. If no proteinuria or microalbuminuria, repeat screen 
in 12 months for those at risk of development of CKD  
      
 
    
Proteinuria or microalbuminuria: exclude potential causes of proteinuria, e.g. fever, 
infection (UTI, STI, tuberculosis), pregnancy, uncontrolled diabetes, uncontrolled 
hypertension, cardiac failure  
Treat comorbid conditions: repeat urine dipstick in 1 month  
If nephrotic, nephritic or nephritic/nephrotic: refer for investigation and management  
Start antiretroviral treatment (ART) 
      
 
 
At follow-up: persistent proteinuria/microalbuminuria and/or creatinine clearance  
  
with kidney ultrasound scan, serological testing for hepatitis C, B, Plasmodium malariae  (if 
appropriate, depending on infections endemic to the region), auto-immune screen 
Refer to a nephrologist, if available  
      
 
              
If unable to refer: ART  –  dose adjust according to eGFR  
If still proteinuric aer 3 months on ART: start antiproteinuric agents 
K+ <5.0 mmol/L: ACE inhibitor or ARB  and check K+ in one week 
K+ >5.0 mmol/L: potassium-binding resin or non-dihydropyridine calcium channel blocker 
(verapamil or diltiazem)  
Manage stage of CKD appropriately   
Gradual up-titration of dose, depending on tolerance and severity of proteinuria 
<60 mL/min/1.73 m2 – protein:creatine ratio or microalbumin:creatine ratio and investigate
Fig. 1. Management algorithm for screening HIV-infected patients for CKD (adapted from Fabian and Naicker[15]).
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appropriate investigation and treatment of those with confirmed 
CKD. 
Other causes of CKD
Other important but less frequently encountered causes of CKD are 
briefly presented, sub-divided into two divisions based on age and 
ethnicity (Table 7).
Additional causes of CKD are renal tuberculosis, sarcoidosis and 
a number of other inherited or acquired but rare conditions. If there 
is any suspicion of any of the abovementioned disorders, timeous 
referral to a nephrologist or specialist physician is important.
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